Literature DB >> 11443050

Negative regulation of ligand-initiated Ca(2+) uptake by PKC-beta II in differentiated HL60 cells.

H M Korchak1, B E Corkey, G C Yaney, L E Kilpatrick.   

Abstract

In phagocytic cells, fMet-Leu-Phe triggers phosphoinositide remodeling, activation of protein kinase C (PKC), release of intracellular Ca(2+) and uptake of extracellular Ca(2+). Uptake of extracellular Ca(2+) can be triggered by store-operated Ca(2+) channels (SOCC) and via a receptor-operated nonselective cation channel(s). In neutrophilic HL60 cells, the PKC activator phorbol myristate acetate (PMA) activates multiple PKC isotypes, PKC-alpha, PKC-beta, and PKC-delta, and inhibits ligand-initiated mobilization of intracellular Ca(2+) and uptake of extracellular Ca(2+). Therefore PKC is a negative regulator at several points in Ca(2+) mobilization. In contrast, selective depletion of PKC-beta in HL60 cells by an antisense strategy enhanced fMet-Leu-Phe-initiated Ca(2+) uptake but not mobilization of intracellular Ca(2+). Thapsigargin-induced Ca(2+) uptake through SOCC was not affected by PKC-beta II depletion. Thus PKC-beta II is a selective negative regulator of Ca(2+) uptake but not release of intracellular Ca(2+) stores. PKC-beta II inhibits a receptor-operated cation or Ca(2+) channel, thus inhibiting ligand-initiated Ca(2+) uptake.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443050     DOI: 10.1152/ajpcell.2001.281.2.C514

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  2 in total

1.  Calcium signalling is altered in myeloid cells with a deficiency in NADPH oxidase activity.

Authors:  B K Rada; M Geiszt; R Van Bruggen; K Nemet; D Roos; E Ligeti
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 2.  Cell signaling through protein kinase C oxidation and activation.

Authors:  Daniela Cosentino-Gomes; Nathália Rocco-Machado; José Roberto Meyer-Fernandes
Journal:  Int J Mol Sci       Date:  2012-08-24       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.